The epidermal-growth factor receptor (EGFR) is another example of RTK that is highly expressed in 90% of HNSCC patients and has been linked to treatment resistance, poor clinical outcomes, and higher fraction of CSCs, which, together with CD44, has been shown to promote tumor initiation and progression in vivo (40). This evidence concerns the gene EGFR and neoplasm.